Stanley Druckenmiller’s Vaxcyte PCVX Stock Holding History

Stanley Druckenmiller’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-86,265	Closed	-$7.06M	–	75
2024 Q4	$7.06M	Buy	86,265 +43,300	+101%	+$4.3M	0.19%	64
2024 Q3	$4.91M	Buy	+42,965	New	+$3.87M	0.17%	63

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Stanley Druckenmiller's PCVX Position: Q1 2025 in Review

Stanley Druckenmiller sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 86,265 shares — an estimated $7.06M sold.

Stanley Druckenmiller first reported a position in PCVX in Q3 2024 and held it in 2 quarters. The position peaked at $7.06M in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Stanley Druckenmiller reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Stanley Druckenmiller sold 86,265 Vaxcyte shares in Q1 2025, an estimated $7.06M.
Stanley Druckenmiller first reported a position in Vaxcyte in Q3 2024 and held it in 2 quarters.
Stanley Druckenmiller's Vaxcyte position peaked at $7.06M in Q4 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Duquesne Family Office's 13F filing for Q1 2025, filed 15 May 2025.